These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 29260104)
1. Treatment of cystic cavities in X-linked juvenile retinoschisis: The first sequential cross-over treatment regimen with dorzolamide. Coussa RG; Kapusta MA Am J Ophthalmol Case Rep; 2017 Dec; 8():1-3. PubMed ID: 29260104 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis. Genead MA; Fishman GA; Walia S Arch Ophthalmol; 2010 Feb; 128(2):190-7. PubMed ID: 20142541 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Ripasudil, a Rho-Associated Coiled/Coil-Containing Protein Kinase Inhibitor, in Improving Retinoschisis and Cystic-Like Foveal Cavities in Eyes with X-Linked Retinoschisis. Suimon H; Sugimoto M; Matsubara H; Kondo M Case Rep Ophthalmol; 2020; 11(2):411-417. PubMed ID: 32999669 [TBL] [Abstract][Full Text] [Related]
4. Use of dorzolamide for patients with X-linked retinoschisis. Apushkin MA; Fishman GA Retina; 2006 Sep; 26(7):741-5. PubMed ID: 16963845 [TBL] [Abstract][Full Text] [Related]
5. POSSIBLE EFFICACY OF TOPICAL DORZOLAMIDE IN THE TREATMENT OF PACLITAXEL-RELATED CYSTOID MACULAR EDEMA. Dwivedi R; Tiroumal S Retin Cases Brief Rep; 2018 Winter; 12(1):75-79. PubMed ID: 27749791 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of Carbonic Anhydrase Inhibitors on Cystoid Fluid Collections and Visual Acuity in Patients with X-Linked Retinoschisis. Hensman J; Hahn LC; van Schooneveld MJ; Diederen RMH; Ten Brink JB; Florijn RJ; Bergen AA; Strubbe I; Heutinck P; van Genderen MM; van den Born LI; Thiadens AA; de Zaeytijd J; Leroy BP; Hoyng CB; Boon CJF Ophthalmol Retina; 2024 Jun; 8(6):600-606. PubMed ID: 38104928 [TBL] [Abstract][Full Text] [Related]
7. Carbonic anhydrase inhibitors limit complications in X-linked retinoschisis. Wey S; Brill DA; Miraldi Utz V; Sisk RA Front Med (Lausanne); 2023; 10():1281068. PubMed ID: 38020097 [TBL] [Abstract][Full Text] [Related]
8. TOPICAL CARBONIC ANHYDRASE INHIBITORS IN THE LONG-TERM TREATMENT OF JUVENILE X-LINKED RETINOSCHISIS. Schmitt MA; Wang K; DeBenedictis MJ; Traboulsi EI Retina; 2022 Nov; 42(11):2176-2183. PubMed ID: 35982512 [TBL] [Abstract][Full Text] [Related]
9. Use of topical dorzolamide for patients with X-linked juvenile retinoschisis: case report. Bastos AL; Freitas Bde P; Villas Boas O; Ramiro AC Arq Bras Oftalmol; 2008; 71(2):286-90. PubMed ID: 18516436 [TBL] [Abstract][Full Text] [Related]
10. Dramatic response to topical dorzolamide in X-linked retinoschisis. Thangavel R; Surve A; Azad S; Kumar V Indian J Ophthalmol; 2020 Jul; 68(7):1466-1467. PubMed ID: 32587200 [TBL] [Abstract][Full Text] [Related]
11. Carbonic Anhydrase Inhibitors for the Treatment of Cystic Macular Lesions in Children With X-Linked Juvenile Retinoschisis. Verbakel SK; van de Ven JP; Le Blanc LM; Groenewoud JM; de Jong EK; Klevering BJ; Hoyng CB Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5143-5147. PubMed ID: 27699410 [TBL] [Abstract][Full Text] [Related]
12. Rebound macular edema following oral acetazolamide therapy for juvenile X-linked retinoschisis in an Italian family. Galantuomo MS; Fossarello M; Cuccu A; Farci R; Preising MN; Lorenz B; Napoli PE Clin Ophthalmol; 2016; 10():2377-2382. PubMed ID: 27932860 [TBL] [Abstract][Full Text] [Related]
13. Regression of taxane-related cystoid macular edema after topical dorzolamide treatment: two case reports. Otsubo M; Kinouchi R; Kamiya T; Yoshida A J Med Case Rep; 2021 Jul; 15(1):355. PubMed ID: 34284818 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of dorzolamide hydrochloride in the management of chronic cystoid macular edema in patients with retinitis pigmentosa. Grover S; Fishman GA; Fiscella RG; Adelman AE Retina; 1997; 17(3):222-31. PubMed ID: 9196934 [TBL] [Abstract][Full Text] [Related]
15. Relation of response to treatment with dorzolamide in X-linked retinoschisis to the mechanism of functional loss in retinoschisin. Walia S; Fishman GA; Molday RS; Dyka FM; Kumar NM; Ehlinger MA; Stone EM Am J Ophthalmol; 2009 Jan; 147(1):111-115.e1. PubMed ID: 18834580 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with retinitis pigmentosa and usher syndrome. Genead MA; Fishman GA Arch Ophthalmol; 2010 Sep; 128(9):1146-50. PubMed ID: 20837798 [TBL] [Abstract][Full Text] [Related]
18. X-linked retinoschisis maculopathy treated with topical dorzolamide, and relationship to genotype. Khandhadia S; Trump D; Menon G; Lotery AJ Eye (Lond); 2011 Jul; 25(7):922-8. PubMed ID: 21527955 [TBL] [Abstract][Full Text] [Related]
19. The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa. Ikeda Y; Hisatomi T; Yoshida N; Notomi S; Murakami Y; Enaida H; Ishibashi T Graefes Arch Clin Exp Ophthalmol; 2012 Jun; 250(6):809-14. PubMed ID: 22215259 [TBL] [Abstract][Full Text] [Related]
20. Cystoid macular lesions are resistant to topical dorzolamide treatment in enhanced S-cone syndrome child. Bušić M; Bjeloš M; Bosnar D; Ramić S; Bušić I Doc Ophthalmol; 2016 Feb; 132(1):67-73. PubMed ID: 26803827 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]